About Mycovia Pharmaceuticals
Mycovia Pharmaceuticals is a company based in Durham (United States) founded in 2018. Mycovia Pharmaceuticals offers products and services including VIVJOA. Mycovia Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$710 K (USD), Grant
Jun 20, 2018
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mycovia Pharmaceuticals
Mycovia Pharmaceuticals offers a comprehensive portfolio of products and services, including VIVJOA.
Capsules used for treating fungal infections in patients.
People of Mycovia Pharmaceuticals
Unlock access to complete
Funding Insights of Mycovia Pharmaceuticals
Investors in Mycovia Pharmaceuticals
Mycovia Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Mycovia Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mycovia Pharmaceuticals
Investment portfolio details for Mycovia Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mycovia Pharmaceuticals
Detailed financials for Mycovia Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mycovia Pharmaceuticals Comparisons
Peer comparison for Mycovia Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mycovia Pharmaceuticals
Mycovia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
Detailed competitors of Mycovia Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mycovia Pharmaceuticals
Complete news archive for Mycovia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mycovia Pharmaceuticals
Mycovia Pharmaceuticals was founded in 2018.
Mycovia Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.
Mycovia Pharmaceuticals's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
Mycovia Pharmaceuticals offers VIVJOA.
Mycovia Pharmaceuticals has 1 investor. Key investors include HHS.